Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

I-Mab ADR (IMAB)

I-Mab ADR (IMAB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,242,719
  • Shares Outstanding, K 76,963
  • Annual Sales, $ 236,420 K
  • Annual Income, $ 72,170 K
  • 60-Month Beta 0.71
  • Price/Sales 22.37
  • Price/Cash Flow 54.03
  • Price/Book 6.52
Trade IMAB with:

Options Overview

Details
  • Implied Volatility 89.83%
  • Historical Volatility 93.86%
  • IV Percentile 76%
  • IV Rank 56.28%
  • IV High 114.74% on 08/30/21
  • IV Low 57.75% on 07/23/21
  • Put/Call Vol Ratio 0.06
  • Today's Volume 104
  • Volume Avg (30-Day) 162
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 66
  • Open Int (30-Day) 136

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.77
  • Number of Estimates 2
  • High Estimate -0.65
  • Low Estimate -0.90
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
56.29 +20.61%
on 08/19/21
80.88 -16.05%
on 09/07/21
-2.28 (-3.25%)
since 08/16/21
3-Month
56.29 +20.61%
on 08/19/21
85.40 -20.49%
on 06/30/21
-3.60 (-5.03%)
since 06/16/21
52-Week
32.64 +108.04%
on 11/09/20
85.40 -20.49%
on 06/30/21
+31.10 (+84.51%)
since 09/16/20

Most Recent Stories

More News
AbbVie (ABBV) to Co-Develop Regenxbio Eye Disease Gene Therapy

AbbVie (ABBV) is set to co-develop Regenexbio's investigational gene therapy for chronic retinal diseases like wet age-related macular degeneration.

ABBV : 108.37 (+0.56%)
RGNX : 44.95 (-0.49%)
GMAB : 42.26 (-1.40%)
IMAB : 68.29 (+0.25%)
I-Mab Added to FTSE ESG Index Series

/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab...

IMAB : 68.29 (+0.25%)
I-Mab Added to FTSE Russell Global Equity Index Series

and , /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced...

IMAB : 68.29 (+0.25%)
I-Mab Announces Upcoming Participation at September Conferences

and , /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced...

IMAB : 68.29 (+0.25%)
Ascendis (ASND) Rallies on First FDA-Approved Drug Skytrofa

Ascendis' (ASND) Skytrofa gets FDA approval for treating growth failure in pediatric patients. The drug is also the first FDA-approved product in the company's portfolio.

PFE : 44.60 (-0.38%)
NVO : 102.56 (+1.27%)
ASND : 158.15 (+0.53%)
IMAB : 68.29 (+0.25%)
I-Mab Announces Establishment of Environmental, Social and Governance Committee

IMAB : 68.29 (+0.25%)
I-Mab to Provide Business and Corporate Updates and Report Financial Results for the Six Months Ended June 30, 2021 on August 31, 2021

and , /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced...

IMAB : 68.29 (+0.25%)
I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plonmarlimab (TJM2) to Treat Patients with Severe COVID-19

and , /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced...

IMAB : 68.29 (+0.25%)
I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease

IMAB : 68.29 (+0.25%)
I-Mab Announces Authorization of a Renewed Stock Repurchase Program by the Company up to US$40 Million

/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that its...

IMAB : 68.29 (+0.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

I-Mab is a clinical stage biopharmaceutical company. It engages in discovery, development and commercialization of biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. I-Mab is based in SHANGHAI, China.

See More

Key Turning Points

3rd Resistance Point 74.27
2nd Resistance Point 72.47
1st Resistance Point 70.30
Last Price 68.29
1st Support Level 66.32
2nd Support Level 64.52
3rd Support Level 62.35

See More

52-Week High 85.40
Last Price 68.29
Fibonacci 61.8% 65.24
Fibonacci 50% 59.02
Fibonacci 38.2% 52.79
52-Week Low 32.64

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar